US Food and Drug Administration approval of esketamine and brexanolone - Archive ouverte HAL Access content directly
Journal Articles The Lancet. Psychiatry Year : 2019

US Food and Drug Administration approval of esketamine and brexanolone

(1) , (2)
1
2

Abstract

In March 2019, The USFood and Drug Administration (FDA) approved twonew antidepressants -esketamine for treatment-resistant depression (TRD)1and brexanolone for postpartum depression (PPD).
Fichier principal
Vignette du fichier
Cristea_et al_2019_US FDA approval of esketamine_accepted.pdf (1.51 Mo) Télécharger le fichier
Origin : Files produced by the author(s)
Loading...

Dates and versions

hal-02363651 , version 1 (18-02-2020)

Identifiers

Cite

Ioana A Cristea, Florian Naudet. US Food and Drug Administration approval of esketamine and brexanolone. The Lancet. Psychiatry, 2019, 6 (12), pp.975-977. ⟨10.1016/S2215-0366(19)30292-5⟩. ⟨hal-02363651⟩
280 View
511 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More